Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

And the key policy change impacts on Pfizer was a reduced ability to raise ... opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again ...

The guidance does not include the potential impact of future tariffs and trade policy changes ... COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

Artificial intelligence (AI) is at the heart of this change ... Pfizer Inc. (NYSE:PFE) made $63.6 billion in 2024, thanks to robust sales of its non-COVID drugs, which saw an operational growth ...

Arvinas forecast the changes will extend its cash runway into the second half of 2028. Under the previous plan, the biotech said it had the cash to fund operations into 2027. Arvinas and Pfizer ...